Diversified Pharmaceutical Services

Procaps Group Update on Third Quarter Results

Retrieved on: 
Tuesday, November 14, 2023
Vitamins, Supplements, Pharmaceutical, Health, Medical Supplies, Diversified Pharmaceutical Services, Cryptocurrency

Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23”).

Key Points: 
  • Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23”).
  • Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call.

Procaps Group to Report Third Quarter and Nine Months 2023 Results on Tuesday November 14, 2023

Retrieved on: 
Friday, November 10, 2023
Vitamins, Supplements, Pharmaceutical, Health, Medical Supplies, Webcast, Diversified Pharmaceutical Services

Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023.

Key Points: 
  • Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023.
  • The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results.
  • To access the call, please use the following information:

Petauri™ Elects William Fleming and James Robinson to Its Board of Directors

Retrieved on: 
Wednesday, December 6, 2023
Paragon, Economics, Policy, Organization, Schering-Plough, Doctor of Pharmacy, DePaul University, Government, Transylvania University, Senior management, Patient, PDP-11, Marketing, University, Cancer, Diversified Pharmaceutical Services, Medicare, Health, General Studies, Biology, Public, Management, Pharmaceutical industry, Pharmacy, Alkermes, Humana

NASHVILLE, Tenn., Dec. 6, 2023 /PRNewswire/ -- Petauri Health, a purpose-built pharmaceutical services platform, announced today that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company's Board of Directors.

Key Points: 
  • NASHVILLE, Tenn., Dec. 6, 2023 /PRNewswire/ -- Petauri Health , a purpose-built pharmaceutical services platform, announced today that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company's Board of Directors.
  • With a nearly 30-year track record at Humana, Dr Fleming is passionate about simplifying healthcare, providing value to consumers, and fostering high-performing teams.
  • Currently the company's Chief Corporate Affairs Officer, William develops and strengthens relationships with government partners to impact public health policy.
  • During his tenure at Humana, William has led various divisions, focusing on clinical integration and improving health outcomes.

Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA

Retrieved on: 
Thursday, October 26, 2023
Steroid, Principal, FDA, Duke University Hospital, Research, University, NF-κB, Dean (education), Associate, Duke University, MDA, Diversified Pharmaceutical Services, Muscular Dystrophy Association, Binghamton University, Medical director, Rare disease, Weight gain, US Food Sovereignty Alliance, Doctor of Philosophy, Catalyst Pharmaceuticals, Vamorolone, Pediatrics, Disease, Clinical trial, Duchenne, Duchenne muscular dystrophy, DMD, Investment, Patient, Griffin, Bone density, Pharmaceutical industry, Nursing

New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).

Key Points: 
  • New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique steroidal anti-inflammatory drug to treat children and adolescents living with Duchenne muscular dystrophy (DMD).
  • This multi-functional drug shows potent inhibition of pro-inflammatory NFkB pathways via high-affinity binding to the glucocorticoid receptor, high-affinity antagonism for the mineralocorticoid receptor, and membrane stabilization properties.
  • This novel therapy, supported in part by MDA Venture Philanthropy, demonstrates similar efficacy to traditional corticosteroids with reduced negative downstream impacts or side effects.
  • “My son was diagnosed with Duchenne muscular dystrophy, and he was the first person dosed with vamorolone right before his 7th birthday.

Water Street Healthcare Partners Appoints Boris Bernstein as Managing Director of Europe

Retrieved on: 
Wednesday, October 18, 2023
Water, History, Knowledge, Diversified Pharmaceutical Services, Growth, Investment, Water Street District (Henderson, Nevada), Water Street, Pharmaceutical industry

CHICAGO, Oct. 18, 2023 /PRNewswire/ -- Water Street Healthcare Partners , an investment firm dedicated to building market leaders in health care, announced today that it has appointed Boris Bernstein as managing director of Europe.

Key Points: 
  • CHICAGO, Oct. 18, 2023 /PRNewswire/ -- Water Street Healthcare Partners , an investment firm dedicated to building market leaders in health care, announced today that it has appointed Boris Bernstein as managing director of Europe.
  • Mr. Bernstein, who has worked with Water Street as an executive advisor for over 10 years, will spearhead the firm's initiatives in Europe focused on investing in and growing mid-market health care businesses.
  • I'm excited to continue to build partnerships with entrepreneurs of health care businesses in Europe.
  • Water Street is currently managing nearly $6 billion of equity capital focused on investing in and growing health care companies.

Water Street Healthcare Partners Appoints Boris Bernstein as Managing Director of Europe

Retrieved on: 
Wednesday, October 18, 2023
Water, History, Knowledge, Diversified Pharmaceutical Services, Growth, Investment, Water Street (Tampa), Water Street, Pharmaceutical industry

CHICAGO, Oct. 18, 2023 /PRNewswire/ -- Water Street Healthcare Partners , an investment firm dedicated to building market leaders in health care, announced today that it has appointed Boris Bernstein as managing director of Europe.

Key Points: 
  • CHICAGO, Oct. 18, 2023 /PRNewswire/ -- Water Street Healthcare Partners , an investment firm dedicated to building market leaders in health care, announced today that it has appointed Boris Bernstein as managing director of Europe.
  • Mr. Bernstein, who has worked with Water Street as an executive advisor for over 10 years, will spearhead the firm's initiatives in Europe focused on investing in and growing mid-market health care businesses.
  • Since its founding, Water Street has facilitated more than 150 investments and acquisitions to build over 40 companies specializing in medical products and diagnostics, pharmaceutical and life sciences, and health care services.
  • Water Street is currently managing nearly $6 billion of equity capital focused on investing in and growing health care companies.

KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma

Retrieved on: 
Monday, October 16, 2023
Professional Services, Health, Asset Management, Research, Science, Pharmaceutical, Biotechnology, Partnership, Diane Fleri, DACH, Drug development, Therapy, Diversified Pharmaceutical Services, Divisional patent application, KKR, Fine chemical, Frontier, Recipharm, Coriolis

KKR, a leading global investment firm, today announced, in partnership with Flerie, the formation of a new global pharma services platform, Frontier Biosolutions (“Frontier”), which will invest in a portfolio of companies focused on specialized pharmaceutical services to advanced therapeutics customers.

Key Points: 
  • KKR, a leading global investment firm, today announced, in partnership with Flerie, the formation of a new global pharma services platform, Frontier Biosolutions (“Frontier”), which will invest in a portfolio of companies focused on specialized pharmaceutical services to advanced therapeutics customers.
  • Frontier will invest in differentiated scientific capabilities and proprietary technology platforms that address critical bottlenecks in the development and manufacturing of advanced therapeutics.
  • As the platform’s foundational investment, funds managed by KKR and Flerie, through Frontier, have invested in Munich-based Coriolis Pharma, a global leader in formulation research and development, analytical services and non-GMP manufacturing of innovative high-value biologics and cell and gene therapy products.
  • “Coriolis Pharma has an industry-leading track record as a global provider of mission-critical, highly specialized formulation development services and a reputation for scientific leadership and complex problem solving.

Healthcare BPO Market size worth USD 747.81 Billion, Globally, by 2028 at 10.61% CAGR: Verified Market Research®

Retrieved on: 
Friday, October 13, 2023
Patent, Hospital, Geography, Health care, IBM, USD, Bank statement, Accenture, Greg Lindberg, Diversified Pharmaceutical Services, Freedom of Establishment and Freedom to Provide Services in the European Union, Insurance, Health, BPO, Medicare, Growth, UnitedHealth Group, Accounting, National Society of Certified Healthcare Business Consultants, Medical tourism, Research, Retail, Pharmaceutical industry, IQVIA, Parexel

JERSEY CITY, N.J., Oct. 13, 2023 /PRNewswire/ -- The Global Healthcare BPO Market is projected to grow at a CAGR of 10.61% from 2021 to 2028, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 211.65 Billion in 2020 and is expected to reach USD 747.81 Billion by the end of the forecast period.

Key Points: 
  • The " Global Healthcare BPO Market Size By Type, By Delivery Mode, By Geographic Scope And Forecast " report has been published by Verified Market Research®.
  • The report provides an in-depth analysis of the global Healthcare BPO Market, including its growth prospects, market trends, and market challenges.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Healthcare BPO Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Healthcare BPO Market into Provider Service, Payer Service, Pharmaceutical Service, And Geography.

Healthcare BPO Market size worth USD 747.81 Billion, Globally, by 2028 at 10.61% CAGR: Verified Market Research®

Retrieved on: 
Friday, October 13, 2023
Patent, Hospital, Geography, Health care, IBM, USD, Bank statement, Accenture, Greg Lindberg, Diversified Pharmaceutical Services, Freedom of Establishment and Freedom to Provide Services in the European Union, Insurance, Health, BPO, Medicare, Growth, UnitedHealth Group, Accounting, National Society of Certified Healthcare Business Consultants, Medical tourism, Research, Retail, Pharmaceutical industry, IQVIA, Parexel

JERSEY CITY, N.J., Oct. 13, 2023 /PRNewswire/ -- The Global Healthcare BPO Market is projected to grow at a CAGR of 10.61% from 2021 to 2028, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 211.65 Billion in 2020 and is expected to reach USD 747.81 Billion by the end of the forecast period.

Key Points: 
  • The " Global Healthcare BPO Market Size By Type, By Delivery Mode, By Geographic Scope And Forecast " report has been published by Verified Market Research®.
  • The report provides an in-depth analysis of the global Healthcare BPO Market, including its growth prospects, market trends, and market challenges.
  • To get market data, market insights, financial statements and a comprehensive analysis of the Global Healthcare BPO Market, please Contact Verified Market Research® .
  • Based on the research, Verified Market Research® has segmented the global Healthcare BPO Market into Provider Service, Payer Service, Pharmaceutical Service, And Geography.

P3 Technologies Secures $10 Million Investment and Acquires Pet Pharmacy

Retrieved on: 
Wednesday, October 11, 2023
Pharmacy, Parent, Diversified Pharmaceutical Services, P3, Growth, Insurance, Acquisition, Prescription, Health, Medical imaging

The $10 million investment comes from a group of strategic investors who recognize P3T's innovative approach to pet healthcare delivery and its commitment to improving patient outcomes.

Key Points: 
  • The $10 million investment comes from a group of strategic investors who recognize P3T's innovative approach to pet healthcare delivery and its commitment to improving patient outcomes.
  • This influx of capital will enable P3 Technologies to accelerate its mission of transforming the healthcare industry through technology-driven solutions and comprehensive patient care services.
  • This investment reaffirms our dedication to enhancing the pet health experience for both pet parents and their providers."
  • In addition to the investment, P3 Technologies has acquired Heartland Veterinary Pharmacy  and VetApproved Pharmacy.